HK Stock Market Move | BAO PHARMA-B (02659) rose nearly 6%, as Chairman of the Board Liu Yanjun increased his shareholding in the company, and the clinical trial application for BJ045 injection was approved.
BAO PHARMA-B (02659) rose nearly 6% intraday. As of press time, it was up 3.16% at HK$8.15, with a turnover of HK$2.9609 million.
BAO PHARMA-B (02659) rose nearly 6% intraday, up 3.16% as of press time at HK$8.15, with a turnover of HK$2.9609 million.
On the news front, the latest data from the Hong Kong Stock Exchange shows that on October 23, Chairman of the Board Liu Yanjun increased his shareholding in BAO PHARMA-B by 102,100 shares at HK$7.4358 per share, for a total amount of approximately HK$759,200. Following the increase, his latest shareholding stands at approximately 26.309 million shares, representing a latest shareholding ratio of 17.05%.
Recently, BAO PHARMA-B announced that the clinical trial application (IND) for BJ045 injection (an anti-enzyme-degradation anti-CD20 monoclonal antibody for subcutaneous administration, collectively referred to as BJ045), independently developed by the company, has been approved by the National Medical Products Administration of the People's Republic of China, and is approved to conduct clinical trials in China. BJ045 is a subcutaneously administered anti-CD20 antibody resistant to IgG-degrading enzyme degradation, with the potential to be used in combination with IgG-degrading enzymes (such as the company's KJ103) for the treatment of moderate-to-severe autoimmune diseases.
Related Articles
HK Stock Market Move | Guangdong Dtech Technology (01377) rose over 5%, with net profit attributable to shareholders for the first three quarters up more than 3-fold year-on-year, and orders for AI PCB-related precision tools and other products surging significantly.
China Securities Co., Ltd.: Clothless technology is driving industry chain value to concentrate in the CCL/PP segments; attention should be paid to incremental opportunities in PCB processing and upstream materials.
HK Stock Market Move | UBTECH ROBOTICS (09880) rises over 8% as the company accelerates its expansion into the European market, with revenue from full-size embodied humanoid Siasun Robot&Automation growing rapidly.
HK Stock Market Move | Guangdong Dtech Technology (01377) rose over 5%, with net profit attributable to shareholders for the first three quarters up more than 3-fold year-on-year, and orders for AI PCB-related precision tools and other products surging significantly.
China Securities Co., Ltd.: Clothless technology is driving industry chain value to concentrate in the CCL/PP segments; attention should be paid to incremental opportunities in PCB processing and upstream materials.
HK Stock Market Move | UBTECH ROBOTICS (09880) rises over 8% as the company accelerates its expansion into the European market, with revenue from full-size embodied humanoid Siasun Robot&Automation growing rapidly.
